glp-1 agonist gastroparesis Researchers find medications safe to continue before surgery in patients with diabetes and obesity Our Pipeline - Neurogastrx, Inc.
Description
Weight Loss: Average weight loss in the LEAD trials was 2 kg to 3.24 kg, with the majority of the reduction noted in the first 4 months of therapy, but tending to be sustained throughout the remaining period of the studies
Accessed 04 Sept 2023
M.HoffmannU.PouK
Youre comfortable with potentially slightly higher side effect rates for better results
2025 May;46(5):422-436
doi: 10.2337/diabetes.47.4.632
